Tech Company Financing Transactions
Egle Therapeutics Funding Round
Horizon Capital participated in a $9.3 million funding round for Egle Therapeutics. The round was announced on 3/2/2026.
Transaction Overview
Company Name
Announced On
3/2/2026
Transaction Type
Debt
Amount
$9,300,000
Round
Undisclosed
Investors
Proceeds Purpose
This funding from the European Union will support an Egle-led initiative in partnership with a consortium of four leading European scientific institutions to advance the clinical development of EGL-001, a novel anti-CTLA-4 x IL-2m fusion protein, and to facilitate a comprehensive translational research program to de-risk later-stage clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
29 Rue du Faubourg St Jacques Pépinière Cochin Paris Santé
Paris, 75014
France
Paris, 75014
France
Phone
Website
Email Address
Overview
Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs' starving while specifically targeting the most immunosuppressive ones.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Luc Boblet
Chief Financial Officer
Stéphane Postic
Browse more venture capital transactions:
Prev: 2/27/2026: Made With Intent venture capital transaction
Next: 3/2/2026: Outpost Bio venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs